Growth hormone secretagogue
GHRP-2 — evidence
What has been published, classified by the kind of document it is. This is not a protocol, not a score, and not a recommendation for use.
Evidence overview
No evidence records in this file yet.
What we know
Editorial reading of the records below, labelled as Therapept analysis. How records are built
What remains uncertain
Regulatory notes
FDA compounding Category 2
- No approved drug product exists in Drugs@FDA.
- Listed by FDA as “Growth hormone releasing peptide-2 (GHRP-2)” on the active Category 2 table for 503B compounding, for injectable and nasal routes of administration, added 29 September 2023.
- FDA's published concerns include immunogenicity risk from aggregation and peptide-related impurities, the added characterisation complexity of an unnatural amino acid, and reports of serious adverse events in patients who received GHRP-2.
- No registered studies were returned by ClinicalTrials.gov for the intervention name GHRP-2 at review.
Regulatory status describes how a substance is classified. It is not a safety assessment of any particular material.
No records in this file match the current filter. That is an empty result, not a finding about the compound.
Last reviewed 15 September 2026 · Compiled by Therapept Editorial · How these records are built